We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akero Therapeutics, Inc. (AKRO - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Akero Therapeutics, Inc. is a member of our Medical group, which includes 973 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Akero Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AKRO's full-year earnings has moved 2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AKRO has returned 73.2% so far this year. At the same time, Medical stocks have lost an average of 2.4%. This means that Akero Therapeutics, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Stryker (SYK - Free Report) . The stock has returned 9.2% year-to-date.
For Stryker, the consensus EPS estimate for the current year has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Akero Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 486 individual stocks and currently sits at #159 in the Zacks Industry Rank. On average, this group has gained an average of 3.3% so far this year, meaning that AKRO is performing better in terms of year-to-date returns.
In contrast, Stryker falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #107. Since the beginning of the year, the industry has moved +7.3%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Akero Therapeutics, Inc. and Stryker as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akero Therapeutics, Inc. (AKRO - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Akero Therapeutics, Inc. is a member of our Medical group, which includes 973 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Akero Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AKRO's full-year earnings has moved 2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AKRO has returned 73.2% so far this year. At the same time, Medical stocks have lost an average of 2.4%. This means that Akero Therapeutics, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Stryker (SYK - Free Report) . The stock has returned 9.2% year-to-date.
For Stryker, the consensus EPS estimate for the current year has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Akero Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 486 individual stocks and currently sits at #159 in the Zacks Industry Rank. On average, this group has gained an average of 3.3% so far this year, meaning that AKRO is performing better in terms of year-to-date returns.
In contrast, Stryker falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #107. Since the beginning of the year, the industry has moved +7.3%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Akero Therapeutics, Inc. and Stryker as they could maintain their solid performance.